Brandon Kaye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brandon Kaye has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Hamid Borghei-Razavi
Department of Neurological Surgery, Pauline Braathen Neurological Center, Cleveland Clinic Florida, Weston, USA
4 shared publications - Michal Obrzut
Department of Neurological Surgery, Pauline Braathen Neurological Center, Cleveland Clinic Florida, Weston, USA
4 shared publications - Raphael Bastianon Santiago
Department of Neurosurgery, Cleveland Clinic Florida, Weston, Florida, USA
4 shared publications - Assad Ali
Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA
2 shared publications Badih Adada
Cleveland Clinic Florida, Department of Neurosurgery, Weston, USA
2 shared publications- Badih Adada
Department of Neurological Surgery, Pauline Braathen Neurological Center, Cleveland Clinic Florida, Weston, USA
2 shared publications
Latest Publications
- 20 August 2025
- Published by Springer Nature in European Spine Journal
- Vol. 35 (5) , 2462-2478
Immune checkpoint inhibitors and other immunotherapies in the treatment of spinal column tumors: A systematic review and Meta-analysis of efficacy, and safety
Purpose Spinal metastases affect up to 70% of systemic cancer patients, with overall survival averaging less than six months. Traditional chemotherapeutic agents have unsatisfactory results, leading to immunotherapy (IT) investigations. There is no clear consensus on the benefits and risks of IT for spinal tumors. This study assesses the current literature to determine IT safety and survival efficacy for tumors involving spinal column. Methods Following PRISMA guidelines, a systematic search was conducted across Embase, Scopus, Web of Science, and PubMed through September 15th, 2024. Patient demographics, disease control, survival, and toxicity were analyzed using R. A meta-analysis was conducted using a random-intercept logistic regression model to evaluate the effectiveness of adjunctive IT for spine tumors. The quality of included studies assessed using the Methodological Index for Non-Randomized Studies (MINORS). Results A total of 416 articles were screened, with 17 included for qualitative analysis. The studies included 727 patients, with excluding cases of unknown primary origin, the most common primary tumor types were lung cancer, followed by renal cell carcinoma, and melanoma. The most common IT treatments in studies that reported specific types were anti-PD-L1, followed by anti-PD-1 treatments. Meta-analysis showed tumor control rates of 80% (95% CI: 71–87%) following adjunctive IT and the pooled toxicity rate was 5% (95% CI: 1–26%), both with low heterogeneity (I² = 0%). With a maximum follow-up period of 97 months on patients with available data, there were 65 recorded deaths (65.7%) which were all in patients with metastatic spine tumors and no death were recorded in primary spine tumors and the log-rank test indicated a significantly higher overall survival (OS) rate for adjunctive IT in patients with primary spine tumors compared to those with metastatic spine tumors (P< 0.0001). The OS rates were 75%, 57%, 38%, 26%, and 16% at 6-, 12-, 24-, 36-, and 60 months post-IT, respectively. Conclusion When used as an adjuvant treatment, IT is associated with a high rate of tumor control and a low rate of toxicity in patients with spinal metastases. Additionally, there is a significant improvement in OS for patients with primary spine tumors compared to those with metastatic spine tumors as an adjuvant treatment. Future studies are warranted to further elucidate the benefits and risks of IT in this patient population as a primary treatment modality.
- 20 August 2025
- Published by Springer Nature in European Spine Journal
- Vol. 35 (5) , 2462-2478
Immune checkpoint inhibitors and other immunotherapies in the treatment of spinal column tumors: A systematic review and Meta-analysis of efficacy, and safety
Purpose Spinal metastases affect up to 70% of systemic cancer patients, with overall survival averaging less than six months. Traditional chemotherapeutic agents have unsatisfactory results, leading to immunotherapy (IT) investigations. There is no clear consensus on the benefits and risks of IT for spinal tumors. This study assesses the current literature to determine IT safety and survival efficacy for tumors involving spinal column. Methods Following PRISMA guidelines, a systematic search was conducted across Embase, Scopus, Web of Science, and PubMed through September 15th, 2024. Patient demographics, disease control, survival, and toxicity were analyzed using R. A meta-analysis was conducted using a random-intercept logistic regression model to evaluate the effectiveness of adjunctive IT for spine tumors. The quality of included studies assessed using the Methodological Index for Non-Randomized Studies (MINORS). Results A total of 416 articles were screened, with 17 included for qualitative analysis. The studies included 727 patients, with excluding cases of unknown primary origin, the most common primary tumor types were lung cancer, followed by renal cell carcinoma, and melanoma. The most common IT treatments in studies that reported specific types were anti-PD-L1, followed by anti-PD-1 treatments. Meta-analysis showed tumor control rates of 80% (95% CI: 71–87%) following adjunctive IT and the pooled toxicity rate was 5% (95% CI: 1–26%), both with low heterogeneity (I² = 0%). With a maximum follow-up period of 97 months on patients with available data, there were 65 recorded deaths (65.7%) which were all in patients with metastatic spine tumors and no death were recorded in primary spine tumors and the log-rank test indicated a significantly higher overall survival (OS) rate for adjunctive IT in patients with primary spine tumors compared to those with metastatic spine tumors (P< 0.0001). The OS rates were 75%, 57%, 38%, 26%, and 16% at 6-, 12-, 24-, 36-, and 60 months post-IT, respectively. Conclusion When used as an adjuvant treatment, IT is associated with a high rate of tumor control and a low rate of toxicity in patients with spinal metastases. Additionally, there is a significant improvement in OS for patients with primary spine tumors compared to those with metastatic spine tumors as an adjuvant treatment. Future studies are warranted to further elucidate the benefits and risks of IT in this patient population as a primary treatment modality.
- 31 October 2023
- Published by Elsevier in World Neurosurgery
- Vol. 181, e562-e566
Surgical Posture with Microscopic Versus Exoscopic Visualization in Anterior Cervical Procedures
- 31 October 2023
- Published by Elsevier in World Neurosurgery
- Vol. 181, e562-e566
Surgical Posture with Microscopic Versus Exoscopic Visualization in Anterior Cervical Procedures
- 27 June 2023
- Published by Elsevier in World Neurosurgery
- Vol. 177, e433-e439
Chiari Malformation Type 1 and Semi-Sitting Position—A Suitable Alternative for Patients with High BMI
- 27 June 2023
- Published by Elsevier in World Neurosurgery
- Vol. 177, e433-e439
Chiari Malformation Type 1 and Semi-Sitting Position—A Suitable Alternative for Patients with High BMI
- Open Access
- 12 May 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (5) , 4946-4956
The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma
Introduction: Glioblastoma (GBM) patients have a 20–30 incidence of venous thromboembolic events. EGFR is a widely used prognostic marker for many cancers. Recent lung cancer studies have described relationships between EGFR amplification and an increased incidence of thromboembolic complications. We aim to explore this relationship in glioblastoma patients. Methods: Two hundred ninety-three consecutive patients with IDH wild-type GBM were included in the analysis. The amplification status of EGFR was measured using fluorescence in situ hybridization (FISH). Centromere 7 (CEP7) expression was recorded to calculate the EGFR-to-CEP7 ratio. All data were collected retrospectively through chart review. Molecular data were obtained through the surgical pathology report at the time of biopsy. Results: There were 112 subjects who were EGFR-amplified (38.2%) and 181 who were non-amplified (61.8%). EGFR amplification status was not significantly correlated with VTE risk overall (p = 0.2001). There was no statistically significant association between VTE and EGFR status after controlling for Bevacizumab therapy (p = 0.1626). EGFR non-amplified status was associated with an increased VTE risk in subjects greater than 60 years of age (p = 0.048). Conclusions: There was no significant difference in occurrence of VTE in patients with glioblastoma, regardless of EGFR amplification status. Patients older than 60 years of age with EGFR amplification experienced a lower rate of VTE, contrary to some reports on non-small-cell lung cancer linking EGFR amplification to VTE risk.
- 12 May 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (5) , 4946-4956
Open AccessThe Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma
Introduction: Glioblastoma (GBM) patients have a 20–30 incidence of venous thromboembolic events. EGFR is a widely used prognostic marker for many cancers. Recent lung cancer studies have described relationships between EGFR amplification and an increased incidence of thromboembolic complications. We aim to explore this relationship in glioblastoma patients. Methods: Two hundred ninety-three consecutive patients with IDH wild-type GBM were included in the analysis. The amplification status of EGFR was measured using fluorescence in situ hybridization (FISH). Centromere 7 (CEP7) expression was recorded to calculate the EGFR-to-CEP7 ratio. All data were collected retrospectively through chart review. Molecular data were obtained through the surgical pathology report at the time of biopsy. Results: There were 112 subjects who were EGFR-amplified (38.2%) and 181 who were non-amplified (61.8%). EGFR amplification status was not significantly correlated with VTE risk overall (p = 0.2001). There was no statistically significant association between VTE and EGFR status after controlling for Bevacizumab therapy (p = 0.1626). EGFR non-amplified status was associated with an increased VTE risk in subjects greater than 60 years of age (p = 0.048). Conclusions: There was no significant difference in occurrence of VTE in patients with glioblastoma, regardless of EGFR amplification status. Patients older than 60 years of age with EGFR amplification experienced a lower rate of VTE, contrary to some reports on non-small-cell lung cancer linking EGFR amplification to VTE risk.
- 30 April 2023
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 229, 107750
Endoscopic endonasal optic nerve sheath decompression (EONSD) for idiopathic intracranial hypertension: Technical details and meta-analysis
- 30 April 2023
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 229, 107750
Endoscopic endonasal optic nerve sheath decompression (EONSD) for idiopathic intracranial hypertension: Technical details and meta-analysis
- Open Access
- 24 October 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (11) , 1549
Regulation of CD4 T Cell Responses by the Transcription Factor Eomesodermin
Central to the impacts of CD4 T cells, both positive in settings of infectious disease and cancer and negative in the settings of autoimmunity and allergy, is their ability to differentiate into distinct effector subsets with specialized functions. The programming required to support such responses is largely dictated by lineage-specifying transcription factors, often called ‘master regulators’. However, it is increasingly clear that many aspects of CD4 T cell immunobiology that can determine the outcomes of disease states involve a broader transcriptional network. Eomesodermin (Eomes) is emerging as an important member of this class of transcription factors. While best studied in CD8 T cells and NK cells, an increasing body of work has focused on impacts of Eomes expression in CD4 T cell responses in an array of different settings. Here, we focus on the varied impacts reported in these studies that, together, indicate the potential of targeting Eomes expression in CD4 T cells as a strategy to improve a variety of clinical outcomes.
- 24 October 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (11) , 1549
Open AccessRegulation of CD4 T Cell Responses by the Transcription Factor Eomesodermin
Central to the impacts of CD4 T cells, both positive in settings of infectious disease and cancer and negative in the settings of autoimmunity and allergy, is their ability to differentiate into distinct effector subsets with specialized functions. The programming required to support such responses is largely dictated by lineage-specifying transcription factors, often called ‘master regulators’. However, it is increasingly clear that many aspects of CD4 T cell immunobiology that can determine the outcomes of disease states involve a broader transcriptional network. Eomesodermin (Eomes) is emerging as an important member of this class of transcription factors. While best studied in CD8 T cells and NK cells, an increasing body of work has focused on impacts of Eomes expression in CD4 T cell responses in an array of different settings. Here, we focus on the varied impacts reported in these studies that, together, indicate the potential of targeting Eomes expression in CD4 T cells as a strategy to improve a variety of clinical outcomes.
- Open Access
- 4 October 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (10) , 7396-7410
Wide Dissection Trans-Sulcal Approach for Resection of Deep Intra-Axial Lesions in Eloquent Brain Areas
Introduction: Resection of intra-axial tumors (IaT) in eloquent brain regions risks major postoperative neurological deficits. Awake craniotomy is often used to navigate these areas; however, some patients are ineligible for awake procedures. The trans-sulcal approach (TScal) was introduced to reduce parenchymal trauma during tumor resection. We report our experiences utilizing TScal for resection of deep IaT located in eloquent areas. Materials and Methods: This is a single-center retrospective analysis of patients who underwent IaT resection in eloquent areas via TScal from January 2013 to April 2021. Seventeen cases were reviewed, and relevant data was collected. Fluorescence-guided surgery with 5-aminolevulinic acid (ALA) and intraoperative ultrasound was performed in some cases. Results: Seventeen patients (10 males, 7 females) averaging 61.2 years-old (range, 21–76) were included in this study. Average length of stay was 4.8 days, and only 2 patients (11.8%) required hospital readmission within 30 days. Gross total resection (GTR) was achieved in 15 patients (88.2%), while subtotal resection occurred in 2 patients (11.8%). Eleven patients (64.7%) reported full resolution of symptoms, 4 patients (23.5%) reported deficit improvement, and 2 patients (11.8%) experienced no change from their preoperative deficits. No patient developed new permanent deficits postoperatively. Discussion: GTR, preoperative deficit reduction, and complications were comparable to awake craniotomy and other TScal studies. Ancillary intraoperative techniques, such as brain mapping, 5-ALA and intraoperative ultrasound, are afforded by TScal to improve resection rates and overall outcomes. Conclusions: TScal can be an option for patients with deep lesions in eloquent areas who are not candidates for awake surgeries.
- 4 October 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (10) , 7396-7410
Open AccessWide Dissection Trans-Sulcal Approach for Resection of Deep Intra-Axial Lesions in Eloquent Brain Areas
Introduction: Resection of intra-axial tumors (IaT) in eloquent brain regions risks major postoperative neurological deficits. Awake craniotomy is often used to navigate these areas; however, some patients are ineligible for awake procedures. The trans-sulcal approach (TScal) was introduced to reduce parenchymal trauma during tumor resection. We report our experiences utilizing TScal for resection of deep IaT located in eloquent areas. Materials and Methods: This is a single-center retrospective analysis of patients who underwent IaT resection in eloquent areas via TScal from January 2013 to April 2021. Seventeen cases were reviewed, and relevant data was collected. Fluorescence-guided surgery with 5-aminolevulinic acid (ALA) and intraoperative ultrasound was performed in some cases. Results: Seventeen patients (10 males, 7 females) averaging 61.2 years-old (range, 21–76) were included in this study. Average length of stay was 4.8 days, and only 2 patients (11.8%) required hospital readmission within 30 days. Gross total resection (GTR) was achieved in 15 patients (88.2%), while subtotal resection occurred in 2 patients (11.8%). Eleven patients (64.7%) reported full resolution of symptoms, 4 patients (23.5%) reported deficit improvement, and 2 patients (11.8%) experienced no change from their preoperative deficits. No patient developed new permanent deficits postoperatively. Discussion: GTR, preoperative deficit reduction, and complications were comparable to awake craniotomy and other TScal studies. Ancillary intraoperative techniques, such as brain mapping, 5-ALA and intraoperative ultrasound, are afforded by TScal to improve resection rates and overall outcomes. Conclusions: TScal can be an option for patients with deep lesions in eloquent areas who are not candidates for awake surgeries.